Hyderabad, Feb. 12 -- Hyderabad-based biopharmaceutical company Biological E. Limited (BE) on Thursday announced that the World Health Organisation (WHO) has granted Phase II Pre-Qualification (PQ) for its Novel Oral Polio Vaccine type 2 (nOPV2).
The Phase II Pre-Qualification covers both the Drug Substance and Drug Product manufactured at Biological E, completing the entire nOPV2 manufacturing chain at a single, integrated facility.
This marks a major expansion of BE's WHO-qualified manufacturing scope beyond Phase I, under which the company had received PQ in June 2024 for drug product manufacturing using externally supplied drug substance.
Biological E. has already manufactured and supplied 700 million doses of nOPV2 to the global sto...